Next 10 |
home / stock / pxxlf / pxxlf news
Patent Term Extension (PTE) approved in Japan for 2 patents related to TWYMEEG ® , extending the product patent life until 2036 Exclusive discussions being finalized with a leading investor to monetize royalties from sales of TWYMEEG ® (Imeglimin) in Japan As of ...
TWYMEEG ® gross sales in Japan for Sumitomo Pharma Fiscal Year 2023 1 reached JPY 4.6 billion (EUR 27.9 million) 2 , exceeding guidance 3 by more than 8% TWYMEEG ® ’s FY 2024 forecast 4 of JPY 11.3 billion (EUR 69.1 million 2 ) would represent ...
TWYMEEG gross sales in Japan should exceed its FY 2023 1 guidance 2 of JPY 4.2 billion (EUR 25.7 million) 3 driven by a favourable sales trend in Japan. Sumitomo Pharma to report full year results on May 14 th , 2024 Company expects TWYMEEG’s FY 2024 4 forecast ...
Exclusive discussions and finalization of related documentation underway with a leading investor to monetize royalties from TWYMEEG ® (Imeglimin) sales in Japan Cash runway estimated to be sufficient until the completion of the transaction expected by the end of April, including ...
TWYMEEG ® sales continue to perform well in Japan with JPY 3.5 billion (EUR 22.4 million 1 ) total sales over the first 3 quarters of 2023 2 , up +170% vs. the corresponding period in 2022. This growth trajectory is in line to meet or potentially surpass Sumitomo Pharma’s ...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced...
The Company remains focused on securing additional financing to execute its strategic plan in rare diseases Exclusive discussions with a leading investor to monetize royalties from TWYMEEG ® (Imeglimin) sales in Japan Advanced discussions with several potential partners f...
TWYMEEG sales in Japan for the last quarter (July-September) grew by 28% over the prior quarter. Current trajectory, if maintained, would lead to higher TWYMEEG annual sales than Sumitomo Pharma’s FY 2023 forecast 1 , which would already represent a 90% increase over the prior year sal...
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced...
News, Short Squeeze, Breakout and More Instantly...
Poxel SA Company Name:
PXXLF Stock Symbol:
OTCMKTS Market:
Patent Term Extension (PTE) approved in Japan for 2 patents related to TWYMEEG ® , extending the product patent life until 2036 Exclusive discussions being finalized with a leading investor to monetize royalties from sales of TWYMEEG ® (Imeglimin) in Japan As of ...
TWYMEEG ® gross sales in Japan for Sumitomo Pharma Fiscal Year 2023 1 reached JPY 4.6 billion (EUR 27.9 million) 2 , exceeding guidance 3 by more than 8% TWYMEEG ® ’s FY 2024 forecast 4 of JPY 11.3 billion (EUR 69.1 million 2 ) would represent ...
TWYMEEG gross sales in Japan should exceed its FY 2023 1 guidance 2 of JPY 4.2 billion (EUR 25.7 million) 3 driven by a favourable sales trend in Japan. Sumitomo Pharma to report full year results on May 14 th , 2024 Company expects TWYMEEG’s FY 2024 4 forecast ...